Navigation Links
Warner Chilcott to Present at the Citi 2011 Global Health Care Conference
Date:2/18/2011

DUBLIN, Feb. 18, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced that its Executive Vice President and Chief Financial Officer Paul Herendeen is scheduled to speak at the Citi 2011 Global Health Care Conference on Wednesday March 2nd at 9:30 a.m. ET.  

The presentation will be simultaneously webcast at http://ir.wcrx.com/events.cfm, with an archived replay of the webcast available shortly thereafter at http://ir.wcrx.com/events.cfm.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-G


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
2. Warner Chilcott to Present at the 29th Annual J.P. Morgan Healthcare Conference
3. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
4. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
5. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
6. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
7. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
8. Warner Chilcott Announces FDA Approval of Next Generation Actonel
9. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
10. Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex®
11. Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ... decade has seen the atopic dermatitis market ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an ... for patients to self-inject prescription drugs in the large ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... expected to grow to $220B by 2018, according to ... type of injector that does not exist today for ...
(Date:1/14/2014)... Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ... Pennsylvania and Pittsburgh ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Describes ... Endothelial Disease, NEW ORLEANS, Nov. 12 In ... Annual Meeting, Massimo Busin,MD, department head and professor of ... technique that significantly improved,results in patients being treated for ...
... 12 Synvista,Therapeutics, Inc. (AMEX: SYI ) ... a 100-patient Phase 2 clinical trial of alagebrium,(ALT-711), ... Advanced Glycation,End-product (AGE)-cross-link breaker, in patients with chronic ... trial evaluating the efficacy and safety of alagebrium) ...
Cached Medicine Technology:Improved Cornea Surgery Technique Provides Enhanced Transplant Success 2Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 2Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 3Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure 4
(Date:3/10/2014)... study by UCLA scientists and colleagues adds further proof ... Raymond Barnhill of UCLA,s Jonsson Comprehensive Cancer Center that ... creeping like tiny spiders along the outside of blood ... , In addition, the new research, published ... that this process is accelerated when the skin cancer ...
(Date:3/10/2014)... widespread test for ovarian cancer reports false-positives in ... the University of Copenhagen working with clinical researchers ... able to halve the number of false-positives. When ... significant number of women from unnecessary worry and ... to save substantial sums just by including ...
(Date:3/10/2014)... A team of scientists at Washington University School of ... Arizona (UA) in Tucson led by Samuel Achilefu have ... visualize cancer cells during surgeries, which glow blue when ... article he coauthored as part of a special section ... on fluorescence molecular imaging that details the development of ...
(Date:3/9/2014)... has found that erlotinib, a targeted antitumor agent, has ... early online in CANCER , a peer-reviewed journal ... larger trials are warranted to determine whether the drug ... the disease. , Nearly half a million new cases ... it the third most common cancer among females. Despite ...
(Date:3/9/2014)... bowel syndrome (IBS) belongs to the most widespread ... per cent of the workload of gastrointestinal physicians. ... is bloating, which reduces quality of life considerably ... quite a long time, IBS was believed to ... this view, recent findings suggest that IBS is ...
Breaking Medicine News(10 mins):Health News:UV light aids cancer cells that creep along the outside of blood vessels 2Health News:New sugar-test to reduce false-positive cancer diagnoses 2Health News:New sugar-test to reduce false-positive cancer diagnoses 3Health News:New high-tech glasses detect cancer cells during surgery 2Health News:Targeted drug may prolong survival of patients with cervical cancer 2Health News:IBS and bloating: When the gut microbiota gets out of balance 2Health News:IBS and bloating: When the gut microbiota gets out of balance 3
... Shortening end caps on chromosomes in human cervical ... sensitivity to radiation treatment and kills them more quickly, ... . Researchers would to like see their laboratory ... edition lead to safer, more effective combination therapies ...
... Nov. 30 (HealthDay News) -- Preliminary research suggests that ... may help cancer patients who receive stem cell transplants ... The drug appears to work by preventing the donor,s ... and causing systemic inflammation. Researchers found that daily ...
... WASHINGTON, DC, November 28, 2011 Not only are working ... experience is more negative as well, according to a new ... Review . "Gender differences in multitasking are not ... Shira Offer, the lead author of the study and an ...
... plans are partnering with physician practices to initiate a range ... these programs have resulted in decreased emergency room (ER) use, ... by the Alliance of Community Health Plans (ACHP), are part ... way community health plans partner with providers to improve care. ...
... HealthDay Reporter , WEDNESDAY, Nov. 30 (HealthDay News) ... and men facing different heart risks even when they have ... Analyzing the results of coronary CT angiographies -- non-invasive ... patients with acute chest pain, scientists from the Medical University ...
... -- A collaborative research group led by researchers ... injection immediately after spinal cord injury can limit pain for ... protein that exists naturally in humans supports the survival, ... cord. The researchers discovered, through testing in an animal model, ...
Cached Medicine News:Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 3Health News:Drug May Dampen Dangerous Side Effect of Stem Cell Transplants 2Health News:Study: Working moms multitask more and have worse time doing so than dads 2Health News:Study: Working moms multitask more and have worse time doing so than dads 3Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Clogged Arteries Pose Different Dangers for Men, Women: Study 2Health News:Clogged Arteries Pose Different Dangers for Men, Women: Study 3Health News:Cleveland researchers find possible breakthrough to relieve pain following spinal cord injury 2
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: